Patient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 Subpopulation

Bondarenko, I.Sezer, A.Kilickap, S.Gumus, M.Ozguroglu, M.Gogishvili, M.He, X.Gullo, G.Rietschel, P.Quek, R. G.2022-12-012022-12-0120220923-7534https://reader.elsevier.com/reader/sd/pii/S0923753422002551?token=F81D614EB86BFF60216085822CE147E22A08EBDDCDE1049DF36DF115BD81C19835D4791709D44FF7BF0D47AEB4A5C1CB&originRegion=eu-west-1&originCreation=20221201121105http://hdl.handle.net/11727/8196enginfo:eu-repo/semantics/openAccessPatient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 SubpopulationconferenceObject338485000778453100114